Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for Lunsumio® (mosunetuzumab), a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies.
FDA grants Priority Review to Roche’s Lunsumio for people with relapsed or refractory follicular lymphoma
July 6, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022